Cannabinoid-improgan cross-tolerance: Improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB1 receptor.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  European Journal of Pharmacology

• Publication date

  2006-11-07

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.EJPHAR.2006.08.035PMID 16989809
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic.

  2006cited by this paper
• In silico patent searching reveals a new cannabinoid receptor.

  2006cited by this paper
• Identification and characterisation of a novel splice variant of the human CB1 receptor

  2005cited by this paper
• Role of lipids and lipid signaling in the development of cannabinoid tolerance.

  2005cited by this paper
• Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.

  2005cited by this paper
• Evidence that (−)-7-hydroxy-4′-dimethylheptyl-cannabidiol activates a non-CB1, non-CB2, non-TRPV1 target in the mouse vas deferens

  2005cited by this paper
• Evidence for novel cannabinoid receptors.

  2005cited by this paper
• Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice.

  2005cited by this paper
• κ‐ and δ‐opioid receptor functional activities are increased in the caudate putamen of cannabinoid CB1 receptor knockout mice

  2005cited by this paper
• Activation of brain stem nuclei by improgan, a non-opioid analgesic.

  2004cited by this paper
• Antinociception and modulation of rostral ventromedial medulla neuronal activity by local microinfusion of a cannabinoid receptor agonist.

  2004cited by this paper
• Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.

  2004cited by this paper
• Improgan antinociception does not require neuronal histamine or histamine receptors.

  2003cited by this paper
• CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity

  2003cited by this paper
• Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor.

  2003cited by this paper
• Inhibition of Improgan Antinociception by the Cannabinoid (CB)1 AntagonistN-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): Lack of Obligatory Role for Endocannabinoids Acting at CB1 Receptors

  2002cited by this paper
• Effect of Chronic Administration ofR-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone Mesylate (WIN55,212-2) or Δ9-Tetrahydrocannabinol on Cannabinoid Receptor Adaptation in Mice

  2002cited by this paper
• Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice.

  2002cited by this paper
• Association of extracellular acetylcholinesterase with gustatory nerve terminal fibers in the nucleus of the solitary tract.

  2001cited by this paper
• Significance of GABAergic systems in the action of improgan, a non-opioid analgesic.

  2001cited by this paper
• Cannabinoid receptors and pain.

  2001cited by this paper
• A role for spinal, but not supraspinal, alpha(2) adrenergic receptors in the actions of improgan, a powerful, non-opioid analgesic.

  2001cited by this paper
• Evidence for a new G protein-coupled cannabinoid receptor in mouse brain.

  2001cited by this paper
• Antinociceptive effects of tetrahydrocannabinol side chain analogs: dependence upon route of administration.

  2000cited by this paper
• Improgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knockout mice.

  2000cited by this paper
• Time course for the induction and maintenance of tolerance to Δ9-tetrahydrocannabinol in mice

  2000cited by this paper
• Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice.

  2000cited by this paper
• Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro.

  2000cited by this paper
• Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro

  1999cited by this paper
• Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.

  1999cited by this paper
• The neurobiology of cannabinoid analgesia.

  1999cited by this paper
• Absence of antinociceptive tolerance to improgan, a cimetidine analog, in rats.

  1998cited by this paper
• Effects of naltrexone and histamine antagonists on the antinociceptive activity of the cimetidine analog SKF92374 in rats.

  1997cited by this paper
• SKF92374, a Cimetidine Analogue, Produces Mechanical and Thermal Antinociception in the Absence of Motor Impairment

  1997cited by this paper
• Characterization of the antinociceptive properties of cimetidine and a structural analog.

  1996cited by this paper
• Characterization of two cloned human CB1 cannabinoid receptor isoforms.

  1996cited by this paper
• Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine.

  1995cited by this paper
• An Amino-terminal Variant of the Central Cannabinoid Receptor Resulting from Alternative Splicing (*)

  1995cited by this paper
• Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212.

  1994cited by this paper
• Cannabinoid-induced antinociception is mediated by a spinal alpha 2-noradrenergic mechanism.

  1991cited by this paper
• Cimetidine penetrates brain and inhibits non-opiate footshock-induced analgesia.

  1986cited by this paper
• Effects of N-hydroxyethyl-pyrrolidinium methiodide, a choline analogue, on passive avoidance behaviour in mice.

  1975cited by this paper
• Decreased rat brain acetylcholine utilization after heroin and cross tolerance to l-methadone.

  1975cited by this paper

• Antinociceptive activity of CC44, a biotinylated improgan congener.

  2013cites this paper
• Neuropharmacology and analgesia Antinociceptive activity of CC 44 , a biotinylated improgan congener

  2013cites this paper
• Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic

  2011cites this paper
• Physiological basis for inhibition of morphine and improgan antinociception by CC12, a P450 epoxygenase inhibitor.

  2010cites this paper
• Neural basis for improgan antinociception.

  2010cites this paper
• Non-opioid antinociception produced by brain stem injections of improgan: significance of local, but not cross-regional, cannabinoid mechanisms.

  2009influential citation
• Improgan-induced hypothermia: a role for cannabinoid receptors in improgan-induced changes in nociceptive threshold and body temperature.

  2007cites this paper
• Significance of cannabinoid CB1 receptors in improgan antinociception.

  2007cites this paper
• Antinociceptive activity of furan-containing congeners of improgan and ranitidine.

  2007cites this paper
• CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonist.

  2007cites this paper